Brought to you by 
Roivant gets rights to Poxel's imeglimin worldwide except in certain Asian countries; Agreement Terminated
15 Jan 2021
Executive Summary
Poxel SA licensed Roivant Sciences GMBH rights to develop and commercialize its Type II diabetes compound imeglimin in the US, Europe, and all other countries except certain Asian territories where Poxel's partner Sumitomo Dainippon Pharma has rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roivant gets rights to Poxel's imeglimin worldwide except in certain Asian countries; Agreement Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice